Patents by Inventor Keiji Furuuchi

Keiji Furuuchi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
    Publication number: 20230398228
    Abstract: Linker toxins and antibody-drug conjugates that bind to human oncology antigen targets such as folate receptor alpha and/or provide anti-tubulin drug activity are disclosed. The linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the antibody-drug conjugates provided herein.
    Type: Application
    Filed: December 7, 2022
    Publication date: December 14, 2023
    Inventors: Earl F. Albone, Xin Cheng, Daniel W. Custar, Keiji Furuuchi, Jing Li, Utpal Majumder, Toshimitsu Uenaka
  • ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
    Publication number: 20200297860
    Abstract: Linker toxins and antibody-drug conjugates that bind to human oncology antigen targets such as folate receptor alpha and/or provide anti-tubulin drug activity are disclosed. The linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the antibody-drug conjugates provided herein.
    Type: Application
    Filed: December 4, 2019
    Publication date: September 24, 2020
    Inventors: Earl F. Albone, Xin Cheng, Daniel W. Custar, Keiji Furuuchi, Jing Li, Utpal Majumder, Toshimitsu Uenaka
  • Eribulin-based antibody-drug conjugates and methods of use
    Patent number: 10548986
    Abstract: Linker toxins and antibody-drug conjugates that bind to human oncology antigen targets such as folate receptor alpha and/or provide anti-tubulin drug activity are disclosed. The linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the antibody-drug conjugates provided herein.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: February 4, 2020
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Earl F. Albone, Xin Cheng, Daniel W. Custar, Keiji Furuuchi, Jing Li, Utpal Majumder, Toshimitsu Uenaka
  • Eribulin-based antibody-drug conjugates and methods of use
    Patent number: 10322192
    Abstract: Linker toxins and antibody-drug conjugates that bind to human oncology antigen targets such as folate receptor alpha and/or provide anti-tubulin drug activity are disclosed. The linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the antibody-drug conjugates provided herein.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: June 18, 2019
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Earl F. Albone, Xin Cheng, Daniel W. Custar, Keiji Furuuchi, Jing Li, Utpal Majumder, Toshimitsu Uenaka
  • ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
    Publication number: 20180193478
    Abstract: Linker toxins and antibody-drug conjugates that bind to human oncology antigen targets such as folate receptor alpha and/or provide anti-tubulin drug activity are disclosed. The linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the antibody-drug conjugates provided herein.
    Type: Application
    Filed: February 9, 2018
    Publication date: July 12, 2018
    Inventors: Earl F. Albone, Xin Cheng, Daniel W. Custar, Keiji Furuuchi, Jing Li, Utpal Majumder, Toshimitsu Uenaka
  • ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
    Publication number: 20170252458
    Abstract: Linker toxins and antibody-drug conjugates that bind to human oncology antigen targets such as folate receptor alpha and/or provide anti-tubulin drug activity are disclosed. The linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the antibody-drug conjugates provided herein.
    Type: Application
    Filed: March 2, 2017
    Publication date: September 7, 2017
    Inventors: Earl F Albone, Xin Cheng, Daniel W. Custar, Keiji Furuuchi, Jing Li, Utpal Majumder, Toshimitsu Uenaka